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AcuteMountain Sickness (AMS) is a common clinical challenge at high altitude (HA). A point-of-care biochemicalmarker for AMS
could have widespread utility. Neutrophil gelatinase-associated lipocalin (NGAL) rises in response to renal injury, inflammation
and oxidative stress. We investigated whether NGAL rises with HA and if this rise was related to AMS, hypoxia or exercise. NGAL
was assayed in a cohort (𝑛 = 22) undertaking 6 hours exercise at near sea-level (SL); a cohort (𝑛 = 14) during 3 hours of normobaric
hypoxia (FiO2 11.6%) and on two trekking expeditions (𝑛 = 52) to over 5000m. NGAL did not change with exercise at SL or
following normobaric hypoxia. During the trekking expeditions NGAL levels (ng/ml, mean ± sd, range) rose significantly (𝑃 <
0.001) from 68 ± 14 (60–102) at 1300m to 183 ± 107 (65–519); 143 ± 66 (60–315) and 150 ± 71 (60–357) at 3400m, 4270m and 5150m
respectively. At 5150m there was a significant difference in NGAL between those with severe AMS (𝑛 = 7), mild AMS (𝑛 = 16)
or no AMS (𝑛 = 23): 201 ± 34 versus 171 ± 19 versus 124 ± 12 respectively (𝑃 = 0.009 for severe versus no AMS; 𝑃 = 0.026 for
mild versus no AMS). In summary, NGAL rises in response to prolonged hypobaric hypoxia and demonstrates a relationship to
the presence and severity of AMS.
1. Introduction
Acute mountain sickness (AMS) occurs during exposure to
high altitude (HA) and is a clinical syndrome characterised by
headache, insomnia, malaise, and gastrointestinal symptoms.
It is common, developing in 10–30% at 2500–3000 meters
[1] and in up to 60% of those ascending to around 4500
meters [2]. It causes significantmorbidity and is a challenging
clinical condition in remote environments. A biochemical
marker of AMS, particularly one available as a point-of-care
test (POC), could have widespread clinical utility.
The pathophysiology of AMS is not clearly understood
but involves alterations in fluid balance, endothelial function,
vascular permeability, inflammation, and oxidative stress.
The renal response to HA is an important factor in acclimati-
zation, and HA exposure leads to renal arteriole constriction
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and relative hypoxia [3, 4]. Despite the relative renal hypoxia,
marked rises in creatinine or overt renal failure are generally
not observed.
NGAL (neutrophil gelatinase-associated lipocalin) is a
25 kDa peptide, part of the lipocalin family of small soluble
proteins. It is produced in a number of human tissues, notably
the distal nephron but also in the lung [5] NGAL rises
rapidly in the nephron in response to a renal insult and an
NGAL ≥150 ng/mL following acute kidney injury (AKI) is
predictive of acute renal failure (ARF) well before creatinine
has risen [6]. NGAL is also an acute-phase protein [7], has
a role in inflammation [8, 9], and is upregulated in the lung
during inflammation [5, 10, 11]. NGAL is also known to rise
in conditions associated with oxidative stress [12, 13], and
oxidative stress has been implicated in AMS [14, 15].
We therefore hypothesised that NGAL would increase
at HA secondary to these various stimuli and that the
magnitude of any increase might relate to the presence of
AMS. We therefore studied a combined cohort of trekkers
from 2 expeditions to HA. In order to clarify the relative
contribution of AMS, hypoxia or exercise to NGAL levels, we
also studied a cohort pre- and postexercise at near sea level,
and a further cohort exposed to acute normobaric hypoxia.
The potential role of inflammation in stimulating NGAL was
assessed by the measurement of highly sensitive C-reactive
protein (hsCRP) in a subset of participants.
2. Materials and Methods
2.1. Ethical Approval. All study protocols were approved by
the Ministry of Defence Research Ethics Committee, White-
hall, UK, and satisfied the requirements of the Declaration
of Helsinki. In all studies informed, written consent was
obtained.
2.2. TREK 1. Thirty-two subjects participating in a Defence
Medical Services (DMS) trekking expedition (TREK 1) in the
Khumbu region of Nepal were studied. Blood samples were
taken from the antecubital fossa at 3 study altitudes: on day
2 at 3400m, day 6 at 4270m, and day 10 at 5150m (following
ascent to Everest Base Camp at 5364m). All samples in this
study were collected immediately following a day trekking
(“posttrek”) to the study altitude.
2.3. TREK 2. Twenty subjects from a further DMS expedi-
tion (TREK 2) to Nepal were also studied. These subjects
followed the same route as in TREK 1. Blood samples were
again taken at 3 study altitudes: on day 2 (3400m), day
6 (4270m), and day 10 (5150m) (following ascent to Kala
Patthar (KP), 5643m). Samples in this study were again
collected immediately following a day trekking (“posttrek”).
Additional samples were taken at rest in Kathmandu (Kat) at
1300m and at rest the next morning at the 3 study altitudes.
Subjects were free to take any medication desired in both
expeditions. No subject took part in both TREK 1 and 2. As
serving members of the military, all subjects were able to
fulfil the fitness criteria of their relevant service. This broadly
includes an age-adjusted ability to run 1.5 miles in under
approximately 11 minutes and to perform an age-adjusted
number of sits-ups and push-ups within two blocks of 2
minutes.
2.4. Hypoxic Chamber Study. Fourteen subjects underwent
a 3-hour exposure to normobaric hypoxia (FiO
2
11.6%,
equivalent to 4800m altitude) in a hypoxic chamber. This
exposure included a 5-minute step test (step height of 25 cm,
1 complete step every 2 seconds) at 95 minutes. NGAL was
assayed at baseline and after 180minutes of hypoxic exposure.
2.5. Near SL Exercise Group. A group of 22 subjects had
NGAL assayed at rest and after exercise at SL in the UK
following ascent from sea level to 1085m over 6 hours (an
equivalent gain in altitude and duration of exercise similar to
that experienced on a trekking day in Nepal). Two subjects
from TREK 2 were part of the SL exercise group, but data
collection occurred several months apart.
2.6. NGAL Assay. NGAL was analysed in the field on a Bios-
ite Triage point of care monitor (Alere Ltd, Stockport, UK)
using a TriageNGAL test kit.TheTriageNGAL test is a point-
of-care, fluorescence-based immunoassay used which gives a
rapid (15 minutes) quantitative measurement of NGAL in a
range from 60 to 1,300 ng/mL.
2.7. Oxygen Saturation Measurement. Oxygen saturation
(digitally on warm hands at rest) was measured using a
Nellcor NP-20 pulse oximeter (Covidian, MA, USA) during
TREK 1+2 and in the hypoxic chamber study at the same time
as blood samples were taken.
2.8. AMS Scores. During TREK 1+2, twice-daily AMS scores
were assessed using the Lake Louise score (LLS) question-
naire [16]. The LLS allocates a score of 0 to 3 (symptom
not present to severe) for symptoms of AMS (headache,
gastrointestinal symptoms, fatigue/weakness, dizzy/light-
headedness, and difficulty sleeping). A score of 3 or more in
the presence of headache is consistent with AMS, a score of 6
or more with severe AMS.
2.9. Assessment of Inflammation. Thecommercially available,
highly sensitive, immunoturbidimetric assay (Roche diag-
nostics) was used to measure CRP in TREK 2 at the same
time points asNGAL.This assay has ameasuring range of 0.1–
300mg/L and a between-run coefficient of variation between
2.5 and 5.7%.
2.10. Statistical Analysis. For statistical calculations, the soft-
ware package SPSS 14.0 was used. For subjects with a NGAL
below the limit of detection of the assay (60 ng/mL), a value
of 60 ng/mL was assigned for the purposes of statistical
analysis. All data were tested for Gaussian distribution using
the Kolmogorov-Smirnov test and Shapiro Wilks statistic.
For the analysis of dependent variables that were nor-
mally distributed, changes were tested by Student’s paired
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𝑡-test. For independent variables that were normally dis-
tributed, an independent-samples 𝑡-test was used. A within-
subjects ANOVA was performed to investigate any serial
changes in NGAL with ascent at rest and post-trek. A two-
way mixed ANOVA with either resting or after trek NGAL
at each study altitude as the within-subjects factor and the
presence of AMS (according to the LL score at multiple
altitudes) as the between-subjects factor was also performed.
If the Mauchly sphericity test was significant, then 𝑃 values
were expressed after multiplication by the Greenhouse-
Geisser epsilon. Correlation analyses for normally distributed
data were performed by calculating the Pearson coefficient
of correlation. A 𝑃 value < 0.05 (two-sided) was considered
significant.
As the ascent profile and route were closely matched in
TREK 1 and TREK 2, data were combined and analysed as
a whole. Taking medication (acetazolamide, dexamethasone)
had no apparent effect on NGAL values, and therefore these
subjects (𝑛 = 11) were not excluded from the analysis.
3. Results
3.1. Demographic Data. Demographic data for the field study
(TREK 1+2), the controls, and the hypoxic chamber study are
shown in Table 1.
3.2. Changes in NGAL and Oxygen Saturation
3.2.1. Near SL Exercise Group. In the 22 subjects ascending to
1085m in the UK, there was no significant (𝑃 = 0.084) rise
in NGAL following exercise: resting SL NGAL was 64 ± 11
(ng/mL, mean ± sd, range 60–104) and postexercise NGAL
was 71 ± 14 (ng/mL, mean ± sd, range 60–100).
3.3. TREK 1+2. Of the 52 subjects, 46 made it to the highest
study altitude (5150m). SpO2 (%,mean ± sem) dropped from
97±2 at Kat (1300m) to 84±5 and 79±7 at 4270 and 5150m,
respectively (𝑃 < 0.001). There was a moderate inverse
correlation between NGAL and SpO2 at 5150m (𝑟 = −0.477,
𝑃 = 0.001) (Figure 1) with a weaker inverse correlation
between NGAL and SpO2 at 4270m (𝑟 = −0.340, 𝑃 = 0.019).
Within the subjects, ANOVA demonstrated a significant
change in NGAL with ascent both at rest (𝑃 = 0.007) and
after trek (𝑃 = 0.001) (Figure 2).
3.4. Normobaric Hypoxia. SpO2 (%, mean ± sem) dropped
from 99 ± 0.4 at baseline to a nadir of 79 ± 5 (𝑃 < 0.001).
Despite an equivalent drop in SpO2 to that seen in TREK 1+2,
NGAL (ng/mL,mean± sd, range) showed no change between
baseline and 180 minutes: 63±26 (29–80) versus 67±25 (27–
84), 𝑃 = 0.538.
3.5. Changes in Renal Function. In TREK 2, serum creatinine
{𝜇mol/L, mean ± sem, (range), (𝑃 value versus baseline at
Kat)}was 78±2 (63–95) at baseline; at 3400, 4270 and 5150m
it was 87 ± 3 (72–120) (𝑃 = 0.001); 84 ± 2 (72–104) (𝑃 <
0.001); and 94 ± 5 (76–142) (𝑃 < 0.001). One subject had a
creatinine level >125 𝜇mol/L.
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Figure 1: Correlation between NGAL and SpO2 at 5150m (𝑟 =
−0.477, 𝑃 = 0.001). A weak inverse correlation between NGAL at
4270m and SpO2 at 4270m (𝑟 = −0.340, 𝑃 = 0.019) was also found.
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Figure 2: NGAL levels at rest and after trek with ascent. NGAL
(ng/mL, mean ± sd, range) at rest at Kat was 68 ± 14 (60–102)
and rose significantly with altitude. The resting values for NGAL
at 3400m, 4270m, and 5150m were 105 ± 68 (60–285); 84 ± 23
(60–134), and 125 ± 35 (67–207), respectively. Posttrek NGAL was
183 ± 107 (65–519); 143 ± 66 (60–315), and 150 ± 71 (60–357) at
3400m, 4270m, and 5150m, respectively. Differences inNGAL after
trek and at rest (compared to baseline) were all significant as was the
repeated measures ANOVA for change in NGAL (𝑃 < 0.01).
3.6. AMS Scores and NGAL. According to their LL scores at
the highest study altitude (5150m), there were 23 subjects
with no AMS, 16 subjects with mild AMS, and 7 subjects
with severe AMS. There was a significant difference between
NGAL depending on the presence or absence of AMS at
5150m (Figure 3) with higher values in those with AMS and
severe AMS. A two-waymixedANOVA revealed a significant
change (𝑃 = 0.003) in resting NGAL with ascent and an
interaction with AMS at 4270m (𝑃 = 0.017) and 4910m
(𝑃 = 0.002 for change in NGAL, 𝑃 = 0.027 for interaction
with AMS).
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Table 1: Demographic data of the subjects studied under 3 different conditions. Data shown are mean ± sem.
TREK 1+2
(𝑛 = 52)
Controls
(𝑛 = 22)
Normobaric hypoxia (NH)
(𝑛 = 14) P value for difference
Sex (M : F) 30 : 22 15 : 7 7 : 7 n.s
Age (years) 35.5 ± 1.1 36 ± 2.4 26.6 ± 1
NH group versus TREK 1 + 2
(𝑃 = 0.003), versus controls
(𝑃 = 0.015)
Weight (kg) 78.2 ± 2.1 79.4 ± 3.2 72.5 ± 3 n.s
Height 174.7 ± 1.3 172.8 ± 1.7 171 ± 3 n.s.
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Figure 3: NGAL levels at 5150m depending on the absence of AMS
(𝑛 = 23, NGAL: 124 ± 12) versusmildAMS (𝑛 = 16, NGAL: 171±19,
𝑃 = 0.026 compared to no AMS) or severe AMS (𝑛 = 7, NGAL:
201 ± 34, 𝑃 = 0.009 for NGAL compared to no AMS).
3.7. Changes in hsCRP. hsCRP was (mean ± sem, range):
1.6±0.4 (0.33–7.53) at baseline; at 3400m, 4270m, and 5150m
post-trek: 7 ± 2.9 (0.78–47.93) (𝑃 = 0.002 versus baseline);
25.7±8.1 (0.58–104) (𝑃 < 0.001 versus baseline); 9±3.2 (0.56–
44.62) (𝑃 = 0.003 versus baseline). At 3400m, 4270m, and
5150m at rest: 6.2±2.9 (1.87–25.1) (𝑃 = 0.001 versus baseline);
21.6±5.7 (0.49–83.9) (𝑃 < 0.001 versus baseline); and 5.8±2.1
(0.54–26.59) (𝑃 = 0.012 versus baseline).
Therewas no significant relationship betweenAMS scores
and hsCRP. NGAL at 5150m, after trek was moderately
correlated with hsCRP at 5100m after exercise (rho 0.526,
𝑃 = 0.036).
4. Discussion
This is the first report to describe an association between
NGAL and both the presence and severity of AMS at HA.
The significant novel findings are thatNGAL rises in response
to sustained hypobaric hypoxia but not acute normobaric
hypoxia or near SL exercise and that this rise is related toAMS
at 5150m.
The rise in NGAL following trekking (by day 2 at 3400m)
was to the levels normally associated with the subsequent
development of ARF (>150 ng/mL), but this did not occur.
Although creatinine rose significantly with altitude, the rise
was verymodest, andwe suspect that a combination of factors
other than a simple renal insult is responsible for the increase
in NGAL at HA.
Our data suggest an inverse correlation between SpO2
and NGAL at 5150m (and to a lesser extent at 4270m).
Although no such correlation was found at 3400m,
this may still suggest that prolonged renal hypoxia could
be a significant drive to NGAL release. Indeed, NGAL has
previously been associated with hypoxaemia in chronic lung
disease [17]. In addition to renal hypoxia, we suspect that
other factors may also contribute to the rise in NGAL at
HA.
The significantly greater NGAL in those with severe or
mild AMS versus those without at 5150m could simply imply
that NGAL rises in those acutely unwell. Indeed, NGAL is an
acute-phase protein [7] with a role in inflammation [8, 10, 11].
Exercise stimulates an immune response [18], and hypoxia is
also known to cause a response in immune and endothelial
cells with inflammatory markers such as hsCRP increasing
with HA [19–22]. Consistent with this, we saw a significantly
higher hsCRP at all altitudes compared to baseline. Limited
data have suggested hsCRP may be associated with AMS [21]
but we did not demonstrate any evidence to support this.
There was a weak correlation between hsCRP and NGAL at
5150m but this cannot explain the rise in NGAL as a whole.
NGAL also rises with oxidative stress [9, 12] which is
increased by exercise [23], and HA-induced oxidative stress
[24] has been implicated inAMS [14]. As such, it is interesting
to note that we found a higher NGAL following trekking and
in those with AMS at the highest altitude.
In an attempt to clarify the relative influence of exercise
and hypoxia on NGAL, we measured NGAL before and after
exercise of a similar duration (6 hrs) and similar incremental
altitude (1085m) as that experienced daily in Nepal and also
in a hypoxic chamber. In neither scenario didNGAL rise.This
may reflect inadequate duration or severity of stimulus but
may also reflect that theNGAL response is not due to exercise
or hypoxia alone but is multifactorial involving hypoxia,
oxidative stress, an inflammatory response, and other, as yet
unidentified, stimuli.
Our data do not imply that NGAL is involved in the
pathogenesis of AMS. We also acknowledge limitations such
as a lack of serum markers of oxidative stress and a lack
of resting NGAL data in TREK 1. In addition, we did not
measure NGAL at SL before departure to Nepal, although
the NGAL recorded as a baseline at Kat (1300m) (68 ng/mL)
was no different to those recorded at SL in the UK (63 and
64 ng/mL). We also acknowledge the fact that although we
measured creatinine in TREK 2, we did not continue to
monitor it after the cessation of trekking. As a consequence
of creatinine rising more slowly in response to a renal insult
than NGAL, we may therefore have missed any later rise in
creatinine.
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5. Conclusion
In conclusion, there are several interesting and novel find-
ings that are worthy of further exploration. NGAL rises in
response to prolonged hypobaric hypoxia; marked increases
in NGAL may occur without concomitant ARF and the
degree of NGAL rise at HA is associated with the presence
or absence of AMS. The fact that NGAL does not appear to
rise secondary to acute normobaric hypoxia or exercise in
isolation suggests that the rise at HA and relation with AMS
may have common pathways, perhaps related to prolonged
hypoxia and an inflammatory response. With the huge and
increasing popularity of recreational sports undertaken at
both moderate and high altitude, the risk of AMS and
the health burden it imposes will remain significant. The
identification of readily available biomarkerswarrants further
investigation. Assessment of NGAL takes a matter of minutes
using POC testing, and its use in identifying AMS requires
further evaluation.
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